Pharming (PHAR) Non-Current Assets (2019 - 2025)

Pharming's Non-Current Assets history spans 7 years, with the latest figure at $200.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $200.5 million for Q4 2025, up 64.96% from a year ago — trailing twelve months through Dec 2025 was $200.5 million (up 64.96% YoY), and the annual figure for FY2025 was $200.5 million, up 64.96%.
  • Non-Current Assets for Q4 2025 was $200.5 million at Pharming, up from $121.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $200.5 million in Q4 2025 to a low of $121.5 million in Q4 2024.
  • The 5-year median for Non-Current Assets is $147.9 million (2021), against an average of $152.9 million.
  • The sharpest move saw Non-Current Assets dropped 17.04% in 2024, then skyrocketed 64.96% in 2025.
  • Year by year, Non-Current Assets stood at $147.9 million in 2021, then grew by 0.29% to $148.3 million in 2022, then decreased by 1.2% to $146.5 million in 2023, then fell by 17.04% to $121.5 million in 2024, then skyrocketed by 64.96% to $200.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $200.5 million, $121.5 million, and $146.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.